Cipla Maroc Pharmaceutical Import Profile — Morocco (DGFT 2022–2026)

Name: Cipla Maroc Pharmaceutical Import Records from India — 6 Products, $15.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla Maroc — Pharmaceutical Importer Profile (2026) | 6 Products, $15.1M Trade | TransData Nexus

Cipla Maroc

Pharmaceutical Importer · Morocco · Respiratory Focus · $15.1M Total Trade · DGFT Verified

Cipla Maroc is a pharmaceutical importer based in Morocco with a total trade value of $15.1M across 6 products in 2 therapeutic categories. Based on 302 verified import shipments from Indian Customs (DGFT) records, Cipla Maroc is the #1 buyer in 2 products including Citalopram, Escitalopram. Cipla Maroc sources from 2 verified Indian suppliers, with Cipla Limited accounting for 74.8% of imports.

Cipla Maroc — Import Portfolio & Supplier Network

Cipla Maroc import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cipla Maroc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$8.7M	473	74.8%
Medispray Laboratories Private Limited	$2.9M	113	25.2%

Cipla Maroc sources from 2 verified Indian suppliers across .

What Formulations Does Cipla Maroc Import?

Formulation	Value	Ships
Saflu 250 inhaler (cfc free)	$2.6M	52
Saflu 250 inhaler (cfc free) (salmeterolxinafoate 25mcg+fluticasone propionate250mcg )(ps:1x120md)	$500.0K	10
Aircort 250mcg inhaler cfc	$400.0K	8
Aircort 250mcg inhaler (cfc free)(beclomethasone dipropionate 250mcg)	$283.8K	9
Foracort 200 inhaler (budesonide 200 MCG	$250.0K	5
S - citap 5 tablet escitalopram	$239.2K	8
Saflu 250 inhaler (cfc free) (salmeterol xinafoate 25mcg+fluticasonepropionate 250mcg) (1 x 120 md)	$233.8K	12
Aircort 250mcg inhaler (cfc free	$196.9K	8
Metanaz nasal suspension (mometasone	$150.0K	3
S-citap 20 tablets escitalopram	$150.0K	3
Tiova rotacaps tiotropium powder for inhalation 18 MCG 16,430 Pack Pack size	$150.0K	3
Tiova rotacaps (tiotropium powder for inhalation 18 MCG)	$150.0K	3
Nazair (fluticasone propionate nasal suspension 50mcg) 1 x 100	$150.0K	3
S-citap 20 tablets (escitalopram oxalate 20MG) (3842 packsx10x10's=384200nos	$149.3K	6
Tiova rotacaps (tiotropium powder for inhalation 18 MCG) (inv.qty.36480 Pack x15s=547200 nos	$138.4K	3

Cipla Maroc imports 236 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Salmeterol	Respiratory	$4.4M	88	6.0%	2
2	Citalopram	CNS & Psychiatric	$3.5M	71	1.4%	1
3	Escitalopram	CNS & Psychiatric	$3.5M	71	1.8%	1
4	Fluticasone	Respiratory	$2.1M	43	1.1%	13
5	Tiotropium	Respiratory	$1.0M	20	1.5%	6
6	Budesonide	Respiratory	$450.0K	9	0.2%	11

Cipla Maroc imports 6 pharmaceutical products across 2 categories into Morocco totaling $15.1M. The company is the #1 buyer for 2 products: Citalopram, Escitalopram.

Cipla Maroc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cipla Maroc is a pharmaceutical importer and distributor based in Casablanca, Morocco. Established in 2015, it operates as a joint venture between Cipla EU Limited, The Pharmaceutical Institute (PHI), and Société Marocaine de Coopération Pharmaceutique (Cooper Pharma). Cipla EU Limited holds a 79.2% stake in the venture, with PHI and Cooper Pharma owning 20.8% collectively. This strategic partnership enables Cipla Maroc to leverage Cipla's extensive global network and expertise in the pharmaceutical industry.

The company's primary focus is on importing and distributing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from India to Morocco. Cipla Maroc plays a significant role in Morocco's pharmaceutical supply chain by ensuring the availability of essential medications, particularly in the respiratory and central nervous system (CNS) therapeutic areas. Its operations contribute to enhancing access to quality healthcare products for the Moroccan population.

2Distribution Network

Cipla Maroc's distribution network is centered in Casablanca, Morocco's commercial hub. While specific warehouse locations are not publicly disclosed, the company's strategic position in Casablanca facilitates efficient logistics and distribution throughout Morocco. The proximity to major ports and transportation infrastructure enables Cipla Maroc to manage imports and deliveries effectively, ensuring timely access to pharmaceutical products across the country.

3Industry Role

Within Morocco's pharmaceutical supply chain, Cipla Maroc functions as a primary wholesaler and distributor. By importing finished pharmaceutical formulations from India, it bridges the gap between international manufacturers and the Moroccan market. Cipla Maroc's role is crucial in ensuring the availability of a diverse range of medications, particularly in the respiratory and CNS therapeutic areas, thereby supporting the healthcare needs of the Moroccan population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cipla Maroc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cipla Maroc's sourcing strategy exhibits a high degree of concentration, with 74.8% of its imports from India sourced from Cipla Limited and 25.2% from Medispray Laboratories Private Limited. This dual-supplier approach suggests a strategic choice to maintain a stable and reliable supply chain. The substantial volume of shipments from these suppliers indicates strong, ongoing relationships, which are essential for ensuring consistent product availability and quality. However, the limited number of suppliers may pose risks related to supply chain disruptions or changes in supplier dynamics.

2Supply Chain Resilience

Cipla Maroc's supply chain resilience is bolstered by its partnership with Cipla Limited, a leading Indian pharmaceutical company with a global presence. Cipla Limited's extensive manufacturing capabilities and established reputation in the industry contribute to a robust supply chain for Cipla Maroc. The focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), allows for greater control over product quality and compliance with regulatory standards. While the reliance on a limited number of suppliers may present challenges, Cipla Maroc's strategic partnerships and product diversification efforts enhance its ability to navigate potential supply chain disruptions.

Strategic Implications

Importing Pharmaceuticals into Morocco — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Morocco

1Regulatory Authority & Framework

In Morocco, the regulatory authority overseeing pharmaceutical imports is the Ministry of Health, which enforces the Code of Medicines and Pharmacy (Law No. 17-04). This legislation governs the registration, manufacturing, distribution, and importation of pharmaceutical products, ensuring they meet the required quality, safety, and efficacy standards. The marketing authorization pathway for Indian generics involves obtaining approval from the Ministry of Health, which includes submitting comprehensive documentation on product quality, clinical efficacy, and safety profiles. Compliance with these regulatory requirements is essential for the successful importation and distribution of pharmaceutical products in Morocco.

2Import Licensing & GMP

Import licensing in Morocco requires pharmaceutical companies to obtain authorization from the Ministry of Health, demonstrating compliance with Good Manufacturing Practice (GMP) standards. Recognized certifications include EU GMP, WHO GMP, and PIC/S. These certifications ensure that imported pharmaceutical products are manufactured in facilities adhering to internationally accepted quality standards. Additionally, wholesale distribution authorization is mandatory, requiring companies to meet specific criteria related to storage, handling, and distribution practices to maintain product integrity and safety.

Cipla Maroc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cipla Maroc's product strategy focuses on two primary therapeutic areas: respiratory and central nervous system (CNS) disorders. The emphasis on respiratory products addresses the significant prevalence of asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis in Morocco. The focus on CNS products caters to the growing demand for treatments for depression, schizophrenia, and bipolar disorders. This strategic alignment with prevalent health conditions in Morocco enables Cipla Maroc to meet critical healthcare needs and expand its market presence.

2Sourcing Profile

Cipla Maroc's sourcing strategy centers on importing finished pharmaceutical formulations from India, particularly from Cipla Limited and Medispray Laboratories Private Limited. This approach ensures access to a diverse range of high-quality products, especially in the respiratory and CNS therapeutic areas. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a strategic sourcing partner for Cipla Maroc. This sourcing profile supports Cipla Maroc's commitment to providing effective and affordable healthcare solutions in Morocco.

3Market Positioning

Seller's Guide — How to Become a Supplier to Cipla Maroc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Cipla Maroc, particularly if they offer products that complement Cipla Maroc's existing portfolio in respiratory and CNS therapeutic areas. Identifying gaps in Cipla Maroc's current sourcing, such as specific formulations or dosage forms not currently imported, can present avenues for partnership. Engaging in discussions with Cipla Maroc to understand their unmet needs and aligning product offerings accordingly can enhance the potential for successful collaboration.

2Requirements & Qualifications

Indian exporters aiming to supply Cipla Maroc and the broader Moroccan market must ensure their products comply with international quality standards, including EU GMP, WHO GMP, or PIC/S certifications. Obtaining marketing authorization from the Moroccan Ministry of Health is essential, which involves submitting comprehensive product dossiers demonstrating quality, safety, and efficacy. Additionally, adherence to Moroccan labeling requirements, including information in Arabic and French, and compliance with serialization mandates are necessary to meet regulatory standards.

3How to Approach

Frequently Asked Questions — Cipla Maroc

What products does Cipla Maroc import from India?

Cipla Maroc imports 6 pharmaceutical products across 2 categories. Top imports: Salmeterol ($4.4M), Citalopram ($3.5M), Escitalopram ($3.5M), Fluticasone ($2.1M), Tiotropium ($1.0M).

Who supplies pharmaceuticals to Cipla Maroc from India?

Cipla Maroc sources from 2 verified Indian suppliers. The primary supplier is Cipla Limited (74.8% of imports, $8.7M).

What is Cipla Maroc's total pharmaceutical import value?

Cipla Maroc's total pharmaceutical import value from India is $15.1M, based on 302 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cipla Maroc focus on?

Cipla Maroc imports across 2 categories. The largest: Respiratory (53.0%), CNS & Psychiatric (47.0%).

Get Full Cipla Maroc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.